No­vo Nordisk's once-week­ly in­sulin will face FDA ad­comm in May, fol­low­ing re­view ex­ten­sion

The FDA’s En­docrino­log­ic and Meta­bol­ic Drugs Ad­vi­so­ry Com­mit­tee will meet on May 24 to dis­cuss No­vo Nordisk’s ap­pli­ca­tion for a once-week­ly in­sulin.

The drug can­di­date, in­sulin icodec, is de­signed to re­duce pa­tients’ basal in­sulin in­jec­tions from sev­en a week to just one. But in De­cem­ber, the FDA told No­vo it would need an ex­tra three months to re­view the ap­pli­ca­tion be­cause of new da­ta that con­sti­tut­ed a “ma­jor amend­ment,” ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER